The DOI matches its Crossref record; 152 of the 155 references it cites were found in a registry or an index, and 1 are not checked yet.
Phenotype plasticity as enabler of melanoma progression and therapy resistance
Open accessAbstract
Malignant melanoma is notorious for its inter- and intratumour heterogeneity, based on transcriptionally distinct melanoma cell phenotypes. It is thought that these distinct phenotypes are plastic in nature and that their transcriptional reprogramming enables heterogeneous tumours both to undergo different stages of melanoma progression and to adjust to drug exposure during treatment. Recent advances in genomic technologies and the rapidly expanding availability of large gene expression datasets have allowed for a refined definition of the gene signatures that characterize these phenotypes and have revealed that phenotype plasticity plays a major role in the resistance to both targeted therapy and immunotherapy. In this Review we discuss the definition of melanoma phenotypes through particular transcriptional states and reveal the prognostic relevance of the related gene expression signatures. We review how the establishment of phenotypes is controlled and which roles phenotype plasticity plays in melanoma development and therapy. Because phenotype plasticity in melanoma bears a great resemblance to epithelial-mesenchymal transition, the lessons learned from melanoma will also benefit our understanding of other cancer types.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, while loss of MITF is sufficient to induce the invasive phenotype, the transition from an invasive to a proliferative phenotype requires the integration of additional signals and epigenetic modifications capable of stably rescuing MITF-driven transcription of proliferation and differentiation genes (67).”
From Secreted Apoe rewires melanoma cell state vulnerability to ferroptosis (2024) · cites this paper as [67]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kaur, A., Webster, M. R., Marchbank, K., Behera, R., Ndoye, A., Kugel, C. H., Dang, V. M., Appleton, J., O’Connell, M. P., Cheng, P., et al. (2016) · Nature · doi:10.1038/nature17392 · Cited by 398
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Greaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162
Cited by
Sorted by citations
Items 301–384 of 384
Advanced omics approaches in liver transplant settings: current applications and future prospectives
Wang, H., Zhou, Y., Yu, L., Liu, Z., & Zheng, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1564248 · Cited by 1
“By enabling the dissection of immune microenvironments, elucidation of injury mechanisms, and discovery of therapeutic targets, scRNA-seq has been widely applied across diverse research domains (26 – 28).”
Vallacchi, V., Lupoli, G., Shahaj, E., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1719461 · Cited by 1
Cai, M., Jia, Y., Fu, T., Kong, J., Qiu, Y., Zhao, Y., Li, X., Yang, Y., & Bai, D. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s575674 · Cited by 1
“83 After surgical resection, infections that occur during the wound healing process often trigger non-tumor -specific inflammatory responses.”
Ailte, I., Chauhan, S. K., Prasmickaite, L., Bassarova, A. V., Poissonnier, A., Feenstra, M., Nyakas, M., Johannessen, B., Ryder, T., Hermann, R., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1815008
“In cutaneous melanoma, stem-like phenotypes are associated with metastatic spread and treatment resistance (18).”
NGFR induces melanoma invasion and immunotherapy resistance through myosin light chain 2 modulation
Nogués, L., Santos, V., García-Agulló, J., Garcı́a-Silva, S., Maiques, Ó., Hernández‐Barranco, A., Mazariegos, M. S., Pérez‐Martínez, M., Torres-Ruiz, R., Saltari, A., et al. (2026) · The EMBO Journal · doi:10.1038/s44318-026-00803-2 · Cited by 1
“…by the ability of tumor cells to adapt to different needs and involves the transition from a proliferative state (MITF + ) towards a dedifferentiated invasive phenotype led by the neural crest marker Nerve Growth Factor Receptor (NGFR) (Arozarena and Wellbrock, 2019; Mehta et al, 2018).”
Anselmi, M., Francesconi, M., Triulzi, T., Bernardo, G., Noci, V. L., Bianchi, F., Castagnoli, L., Arnaboldi, F., Gagliano, N., Pupa, S. M., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1698412 · Cited by 1
Xu, Z., Ugurbil, A., Kwan, J., Schaefer, C., Abdulraouf, A., Lu, Z., Tang, E., Zhou, W. Y., & Cao, J. (2026) · Nature Communications · doi:10.1038/s41467-026-75360-7 · Cited by 1
“Notably,manyTFsweidenti fi edasmelanomasubtype-speci fi carealso key regulators of melanoma phenotypic switching, including SOX10 and MITF in melanocytic differentiation and FOSL1 and JUN in the development of the undifferentiated state 104 .”
Mineral–Botanical Hybrid Nanofibrous Dressing for Post-Surgical Melanoma Wound Healing
Avci, T., Altan, E., Aytar, C., et al. (2026) · Polymers · doi:10.3390/polym18151857 · Cited by 1
“When evaluated alongside the MTT viability results, which demonstrated profound cytotoxicity against A375 cells, this enhanced migration on the Inula-coated scaffolds reveals a classic phenotype switching in melanoma cells [68].”
InfluentialLapkina, E. Z., Palkina, N. V., Сергеевич, А. А., et al. (2022) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2022-21-3-61-69 · Cited by 1
Kispál, M. T., Jánváry, L. Z., Balatoni, T., et al. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610550 · Cited by 1
“This type of progression is related to acquired resistance, and biologically different from generalized progression, which is caused by pre-existing or secondary therapeutic resistance (14).”
BackgroundZheng, Y., Jiang, P., & Zhang, L. (2023) · Dermatologica Sinica · doi:10.4103/ds.ds-d-22-00141 · Cited by 1
Chitosan Nanoparticles as Next Generation of Drug Carriers for Melanoma Treatment: A Review
Ren, X., Jiang, Q., Zeng, Y., & Wang, L. (2023) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2023.3598 · Cited by 1
Protein Kinase C Inhibition Overcomes Targeted Therapy Resistance in Cutaneous Melanoma
Stoffel, C. I., Eichhoff, O. M., Cheng, P. F., Seiler, L., Tellenbach, F. L., Dzung, A., Chiovaro, F., Dummer, R., & Levesque, M. P. (2025) · Experimental Dermatology · doi:10.1111/exd.70093 · Cited by 1
“Moreover, chronic exposure of MAPK inhibitor-sensitive cell cultures induced a transcriptional phenotype switch and the adoption of a mesenchymal expression pattern [10, 14, 15].”
Zhang, Y., Belote, R. L., Urquijo, M. A., Hansen, M. M. K., Hejna, M., Moustafa, T. E., Liu, T., Lange, D., Vand‐Rajabpour, F., Chang, M., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.26.269126 · Cited by 2
TFIIH kinase CDK7 antagonizes phenotype switching and emergence of drug tolerance in melanomaPreprint
Berico, P., Cigrang, M., Braun, C., Davidson, G., Sandoz, J., Gras, S. L., Peyresaubes, F., Robles, C. M. G., Egly, J., Compe, E., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.24.311431 · Cited by 1
“Studies have shown that tolerance to targeted therapies can involve various phenotype changes including the EMT-like process of melanocytic to mesenchymal phenotype switching (Arozarena and Wellbrock, 2019; Kemper et al., 2014; Rambow et al., 2019; Rambow et al., 2018).”
BackgroundHan, H., Wang, Y., Curto, J., Gurrapu, S., Laudato, S., Rumandla, A., Chakraborty, G., Wang, X., Chen, H., Jiang, Y., et al. (2021) · Research Square · doi:10.1101/2021.04.14.439569 · Cited by 1
“In contrast, exposure to BRAF and MEK kinase inhibitors induces a drug-tolerant state in melanoma by directly reprogramming highly proliferative MITFhigh-AXLlow tumor cells into MITFlow-AXLhigh quiescent tumor cells (Arozarena and Wellbrock, 2019).”
BackgroundLotti, F., Marine, M., Malferrari, M., Nicolò, Q., Rapino, S., Velia, M., Ilaria, F., Vlachou, T., Bossi, D., Pelicci, P. G., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.31.551214 · Cited by 1
Ohnmacht, A. J., Avar, G., Schübel, M. K., O’Neill, T. J., Krappmann, D., & Menden, M. P. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.16.575190 · Cited by 2
“…act as a phenotype-switching regulator in melanoma, for which cells with trace MITF levels show senescent properties characterised by cell cycle arrest and cell motility, low-to-intermediate MITF levels display proliferative properties, and higher MITF levels can drive cell differentiation 35–38 .”
BackgroundRovera, C., Berestjuk, I., Lecacheur, M., Diazzi, S., Mallavialle, A., Albrengues, J., Gaggioli, C., Girard, C. A. J., Passeron, T., Deckert, M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.25.436913
“(B) LN-F-mediated collagen matrix contraction after 7 days incubation with CM from dedifferentiated MITFlow AXLhigh or melanocytic MITFhigh AXLlow short term patient melanoma cells (n = 3, in triplicate; mean +/- SEM; p-Val (*)<0.05, (**)<0.01).”
BackgroundInfluentialLi, W., Xiao, H., Xu, X., & Zhang, Y. (2020) · Research Square · doi:10.21203/rs.3.rs-129680/v1
Sala, M., Allain, N., Jabouille, A., Henriet, E., Hammoud, A. A., Uguen, A., Di-Tommaso, S., Dhourte, C., Raymond, A., Dupuy, J., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/857904
Understanding the Role of Plasticity in Glioblastoma
Horak, V. J., Mishory, A., Baisiwala, S., & Ahmed, A. U. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00062-1
Xu, Y., Zheng, J., Cai, Z., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.773101
“However, due to complex intertumor and intratumor heterogeneity, cancer patients with such histological diagnoses often suffer from receiving effective drug treatment and therapeutic resistance (Bedard et al., 2013; Arozarena and Wellbrock, 2019; Ding et al., 2019).”
BackgroundSchefler, A. C. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737263982.793585176
Li, G. (2022) · Research Square · doi:10.21203/rs.3.rs-269749/v1
Skalet, A. H. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737263982.793578662
Huang, F., Cai, F., Dahabieh, M. S., Gunawardena, K., Talebi, A., Dehairs, J., El-Turk, F., Park, J. Y., Gonçalves, C., Gagnon, N., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.25.513718
“phenotype switching/dedifferentiation (3, 4).”
BackgroundYTHDF3 promotes melanoma metastasis by reading N6‐methyladenosine
Cheng, I. Y., & Wong, C. (2022) · Clinical and Translational Discovery · doi:10.1002/ctd2.147
Wang, D., guo, Y., Shen, R., Yang, K., Wang, Y., Song, H., Liu, X., Cheng, X., Wu, R., & Song, Y. (2023) · Research Square · doi:10.21203/rs.3.rs-2353854/v1
A Comprehensive Analysis of Cutaneous Melanoma Patients in Greece Based on Multi-Omic Data
Kontogianni, G., Voutetakis, K., Piroti, G., Kypreou, K. P., Stefanaki, I., Vlachavas, E., Pilalis, E. D., Stratigos, A., Chatziioannou, A. A., & Papadodima, O. (2023) · Cancers · doi:10.3390/cancers15030815
“Recently, “unlocking phenotype plasticity” was proposed as a discrete hallmark capability of cancer cells [24], determining melanoma progression and therapy resistance [22].”
BackgroundMelanoma in Iranian Childhood and Adolescence: An Analysis of 14 Patients
Rakhshan, A., Moradi, A., & Masoudi, E. (2023) · International Journal of Cancer Management · doi:10.5812/ijcm-121873
Yan, M., & Liu, Q. (2023) · Frontiers of Medicine · doi:10.1007/s11684-022-0975-5 · Cited by 1
Rovera, C., Berestjuk, I., Lecacheur, M., Tavernier, C., Diazzi, S., Pisano, S., Irondelle, M., Mallavialle, A., Albrengues, J., Gaggioli, C., et al. (2023) · doi:10.1158/0008-5472.c.6513435.v1
Research Progress of Single Cell Transcriptome Sequencing Technology in Cutaneous Malignant Melanoma
王, 晓. (2023) · Hans Journal of Biomedicine · doi:10.12677/hjbm.2023.132023
Peroxirredoxina 2 na modulação do fenótipo invasivo em melanoma com mutação em NRAS
Noma, I. H. Y. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.9.2023.tde-15052023-111802
Tang, F. R., Lan, T., Liu, Z., Wang, X., & Li, Z. (2023) · medRxiv · doi:10.1101/2023.08.29.23294599
Uncovering Minimal Pathways in Melanoma InitiationPreprint
Xiao, H., Shiu, J., Chen, C., Wu, J., Zhou, P., Telang, S. S., Ruiz, R., Nie, Q., Lander, A. D., & Ganesan, A. K. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.08.570336 · Cited by 1
Deng, G., Wang, W., Li, Y., Sun, H., Chen, X., & Zeng, F. (2021) · Figshare · doi:10.6084/m9.figshare.17066194
Resolving malignant cell heterogeneity from bulk tumor RNA-seq data with CDStatePreprint
Kraft, A., Yates, J., Barkmann, F., & Boeva, V. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.01.641017
Tian, J., Zhang, L., Zhuang, L., Lin, P., Zhang, S., Yan, Y., Yang, Y., Zhang, G., Li, H., & Lai, B. (2025) · Theranostics · doi:10.7150/thno.99526 · Cited by 1
“Considering the biological characteristics of melanoma, it has been assumed that two main melanoma states, proliferation and invasion [44-46], are closely associated with MITF expression level.”
Rincon, S. V. D., Cai, F., Huang, F., Gonçalves, C., Srikannan, H., Gagnon, N., Guettler, E. M., Mukeba-Harchies, L., Maxwell, J., Su, J., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6857127/v1
Deng, G., Wang, W., Li, Y., Sun, H., Chen, X., & Zeng, F. (2021) · Figshare · doi:10.6084/m9.figshare.17066182
Belli, V., Napolitano, S., Falco, V. D., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26565399
Song, Y., Deng, Z. C., Sun, H., Zhao, Y., Zhao, R., Cheng, J., & Huang, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26597633
Deng, G., Wang, W., Li, Y., Sun, H., Chen, X., & Zeng, F. (2021) · Figshare · doi:10.6084/m9.figshare.17066191
Song, Y., Deng, Z. C., Sun, H., Zhao, Y., Zhao, R., Cheng, J., & Huang, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26597618
Song, Y., Deng, Z. C., Sun, H., Zhao, Y., Zhao, R., Cheng, J., & Huang, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26597615
Deng, G., Wang, W., Li, Y., Sun, H., Chen, X., & Zeng, F. (2021) · Figshare · doi:10.6084/m9.figshare.17066179
Deng, G., Wang, W., Li, Y., Sun, H., Chen, X., & Zeng, F. (2021) · Figshare · doi:10.6084/m9.figshare.17066188
Song, Y., Deng, Z. C., Sun, H., Zhao, Y., Zhao, R., Cheng, J., & Huang, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26597612
Song, Y., Deng, Z. C., Sun, H., Zhao, Y., Zhao, R., Cheng, J., & Huang, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26597642
Song, Y., Deng, Z. C., Sun, H., Zhao, Y., Zhao, R., Cheng, J., & Huang, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26597624
Song, Y., Deng, Z. C., Sun, H., Zhao, Y., Zhao, R., Cheng, J., & Huang, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26597627
Song, Y., Deng, Z. C., Sun, H., Zhao, Y., Zhao, R., Cheng, J., & Huang, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26597639
Deng, G., Wang, W., Li, Y., Sun, H., Chen, X., & Zeng, F. (2021) · Figshare · doi:10.6084/m9.figshare.17066185
Song, Y., Deng, Z. C., Sun, H., Zhao, Y., Zhao, R., Cheng, J., & Huang, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26597621
Song, Y., Deng, Z. C., Sun, H., Zhao, Y., Zhao, R., Jin, C., & Huang, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26597630
Song, Y., Deng, Z. C., Sun, H., Zhao, Y., Zhao, R., Cheng, J., & Huang, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26597636
Garcia-Perez, A., Sanchez-Garcia, L., Duran-Renieblas, M., Sella, F., Novo-Acedo, S., Delgado-Lopez, A., Barreno, A., Gracia, J., Rios, C., Young, E. J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.03.686756
“Then we tested a melanoma culture with dedifferentiated phenotype, which are usually intrinsically resistant to MAPKi (8,22,27,48).”
Betti, M., Accetta, C., Arteni, B. A. M., Rosselli, A., Melucci, E., Visca, P., Botti, C., Pelle, F., Russillo, M., Ferraresi, V., et al. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03646-1
Identification et modulation des voies moléculaires impliquées dans l’agressivité du mélanome cutané
Gautron, A. (2019) · theses.fr (ABES) · doi:10.70675/b9c75939z7407z49abzafcbze6e92703d459
Caractérisation du rôle de GAB2 et MITF dans les cellules de mélanome
Kim-Penard, H.-Y. (2019) · theses.fr (ABES) · doi:10.70675/5d393d17z0891z41e1zb35az0913c3882eec
Florent, L. (2024) · theses.fr (ABES) · doi:10.70675/88568e70z24dfz47bfzba55z457d2e65d84d
Su, Y., Liu, C., Lu, X., Chuang, H.-Y., Li, G., Shao, S., Kong, Y., Lee, J. W., Ng, R. H., Wong, S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71349-4 · Cited by 14
“Despite extensive analysis of resultant dedifferentiated DTPs in previous studies 4,12 – 14 , how this dynamic dedifferentiation program is mechanistically initiated under therapeutic stress and whether it is orche-strated by temporally ordered transcriptional waves akin to those in developmental…”
InfluentialMelanoma cell states define therapeutic vulnerabilities in a multimodal single-cell atlasPreprint
Levesque, M. P., Wegmann, R., Chevrier, S., Lehmann, K.-V., Prummer, M., Tusup, M., Gut, G., Casanova, R., Kuipers, J., Lischetti, U., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9413884/v1 · Cited by 1
Wang, Q., & Zhu, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1820654
“The metabolic plasticity of melanoma cells enables them to adapt to RCD induction, potentially undermining treatment ef fi cacy (228).”
Micropillar Topography Regulates Morphology and Melanogenesis in Melanoma Cells
Jeong, H., Tsutsumi, K., Matsunobu, S., et al. (2026) · Journal of Functional Biomaterials · doi:10.3390/jfb17060269
DDERMMAL, a melanocytic long non-coding RNA, confers DNA damage tolerance to melanoma cells
Adnane, S., Verheyden, Y., Cuomo, A., Bonaldi, T., & Leucci, E. (2026) · iScience · doi:10.1016/j.isci.2026.116251
A Rapid 3D Melanoma–Skin Organoid for High-Throughput Assessment of Tumor Dynamics and Drug Response
Nomdedeu‐Sancho, G., Edenhoffer, N. P., Gorkun-Roeder, A., Gaser, O. A., Kengla, C., Benton, A., Mullins, D. W., Atala, A., & Söker, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27125314
Knowledge-guided contextual gene set analysis with large language models
Wang, Z.-Z., Day, C.-P., Wei, C.-H., Jin, Q., Leaman, R., Yang, Y.-F., Tian, S., Qiu, A., Fang, Y., Zhu, Q.-Q., et al. (2026) · Bioinformatics · doi:10.1093/bioinformatics/btag214 · Cited by 1
“This observation is consistent with prior studies reporting that therapeutic resistance in melanoma is associated with transcriptional reprogramming toward mesenchymal-like phenotypes (Arozarena and Wellbrock 2019).”
Ahmad, Z. E., Ludwig, K., Matthies, A. O., Bosserhoff, A., & Kappelmann‐Fenzl, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146459
“Recent therapeutic advances, including immune checkpoint inhibitors and BRAF/MEK-targeted therapies, have improved outcomes, but resistance and relapse remain major challenges [3,4].”
Oxidative stress‐driven metabolic reprogramming defines two subtypes of cutaneous melanoma
Gao, Q., Liu, Z., & Xu, Y. (2026) · Open Research (University of Surrey) · doi:10.1002/viw2.70183
CDState Resolves Malignant Cell Heterogeneity from Bulk Tumor RNA Sequencing Data
Kraft, A., Yates, J., Barkmann, F., & Boeva, V. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-4102
Lei, Y., Zhang, Y., Ma, Z., Hong, X., Wang, Y., & Liu, Y. (2026) · Cellular Signalling · doi:10.1016/j.cellsig.2026.112828
Unique Features of Melanoma Risk and Diagnosis in Red-Haired Populations
Ebrahimi, K., Ostrowski, S. M., & Fisher, D. E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177765
“Fourth, therapy-induced dedifferentiation can suppress melanocytic markers and pigmentation in treated tumors, a setting that is biologically distinct from an untreated primary melanoma that appears amelanotic at diagnosis [86,87].”
Bian, H., Ma, D., Pan, F., Guo, Z., Song, H., Nan, Y., Kim, I. Y., Zhou, D., Li, H., Chen, X., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c13134
From MAPK Reactivation to Response: Clinical Approaches Targeting BRAF/MEK Resistance in Melanoma
Topcu, T. O., Dinçkal, Ç., & Eroglu, Z. (2026) · American Journal of Clinical Dermatology · doi:10.1007/s40257-026-01080-9
Metadata
- Authors
- Arozarena, I., & Wellbrock, C.
- Affiliations
- Universidad Pública de Navarra (UPNA) (ES)
- University of Manchester (GB)
- Corresponding author
- Arozarena, Imanol
- Wellbrock, Claudia
- Venue
- Nature Reviews Cancer
- Published
- 2019-06-17
- Volume
- 19
- Issue
- 7
- Pages
- 377-391
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2950011075
- Semantic Scholar
- 92b52772c2e1273d54d8a8ce6b7911e17f048976
- Cited by
- 381
- References
- 155
- Citations by year
- 2026: 32 · 2025: 40 · 2024: 48 · 2023: 70 · 2022: 62 · 2021: 57 · 2020: 55 · 2019: 17
- FWCI
- 4.22
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, other-oa)
- Funders
- Cancer Research UK (16416, C11591/A16416)
- Instituto de Salud Carlos III (CP15/00176)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- melanoma, phenotypic plasticity, melanoma progression, treatment resistance, targeted therapy resistance, immunotherapy resistance, tumor heterogeneity, gene expression signatures, transcriptional reprogramming, epithelial-mesenchymal transition, prognostic factors
- MeSH terms
- Adaptation, Physiological, Humans, Immunotherapy, Melanoma, Phenotype, Disease Progression, Drug Resistance, Neoplasm, Epithelial-Mesenchymal Transition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
